Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with Respiratory syncytial virus immune globulin
Respiratory syncytial virus infections have been implicated in the development of asthma. We evaluated the long-term effects of respiratory syncytial virus immune globulin, an effective prophylactic agent for the prevention of these infections in children, on respiratory and allergic outcomes in chi...
Gespeichert in:
| Veröffentlicht in: | The American journal of medicine 2002-06, Vol.112 (8), p.627-633 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 633 |
|---|---|
| container_issue | 8 |
| container_start_page | 627 |
| container_title | The American journal of medicine |
| container_volume | 112 |
| creator | WENZEL, Sally E GIBBS, Robyn L LEHR, Marsha V SIMOES, Eric A. F |
| description | Respiratory syncytial virus infections have been implicated in the development of asthma. We evaluated the long-term effects of respiratory syncytial virus immune globulin, an effective prophylactic agent for the prevention of these infections in children, on respiratory and allergic outcomes in children at high risk of chronic airway disease.
Thirteen children at high risk of respiratory disease (mean [+/-SD] age, 8.6 +/- 1.1 years) were evaluated using pulmonary function and allergy skin testing 7 to 10 years after they had received prophylaxis with respiratory syncytial virus immune globulin. For comparison, 26 high-risk control children (mean age, 8.5 +/- 0.9 years) were also evaluated. Health outcomes data were collected from all subjects. The children were matched for age and gestational age. There were more boys, and a lesser frequency of a lower respiratory tract infection with respiratory syncytial virus (P |
| doi_str_mv | 10.1016/S0002-9343(02)01095-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71737234</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71737234</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-1c66656722a59a3f219911c2035ffe92bccd82e9ec20c63f2a83956e5fc5b8e53</originalsourceid><addsrcrecordid>eNpdkV9LHDEUxUOx1HX1I7QEoVIfRnOTTWbnURZtBaHgn-eQzd5xYjOTbTLTOvTLm9VFpU-X5P7u4d5zCPkM7AQYqNMbxhgvKjET3xg_ZsAqWcAHMgEpZVGC4jtk8orskr2UHvIzU-oT2QXOxGwGfEL-XWNau2j6EEcaht6GFhN1HW3cfVNEl35R2zi_itjRkvaBAqMjmpioqXuMdB3Duhm9eXSJ_nV9Q9_rpbGzY--Mp39cHLJs2w4d0nsfloN33T75WBuf8GBbp-Tu4vx28aO4-vn9cnF2VViheF-AVUpJVXJuZGVEzaGqAGw-QdY1Vnxp7WrOscL8ZVXum7nIZ6KsrVzOUYopOXrRzcv-HjD1unXJovemwzAkXUIpSp5tmpLD_8CHMMQu76a54CJbNttA8gWyMaQUsdbr6FoTRw1Mb6LRz9Hoje861-doNOS5L1vxYdni6m1qm0UGvm4Bk6zxdTSddemNEznVuWTiCR0ql8E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>232334444</pqid></control><display><type>article</type><title>Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with Respiratory syncytial virus immune globulin</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>WENZEL, Sally E ; GIBBS, Robyn L ; LEHR, Marsha V ; SIMOES, Eric A. F</creator><creatorcontrib>WENZEL, Sally E ; GIBBS, Robyn L ; LEHR, Marsha V ; SIMOES, Eric A. F</creatorcontrib><description>Respiratory syncytial virus infections have been implicated in the development of asthma. We evaluated the long-term effects of respiratory syncytial virus immune globulin, an effective prophylactic agent for the prevention of these infections in children, on respiratory and allergic outcomes in children at high risk of chronic airway disease.
Thirteen children at high risk of respiratory disease (mean [+/-SD] age, 8.6 +/- 1.1 years) were evaluated using pulmonary function and allergy skin testing 7 to 10 years after they had received prophylaxis with respiratory syncytial virus immune globulin. For comparison, 26 high-risk control children (mean age, 8.5 +/- 0.9 years) were also evaluated. Health outcomes data were collected from all subjects. The children were matched for age and gestational age. There were more boys, and a lesser frequency of a lower respiratory tract infection with respiratory syncytial virus (P <0.001) in the group that had been treated prophylactically than in the controls. The ratio of the forced expiratory volume in 1 second to forced vital capacity was significantly better in children who had received immune globulin (median, 0.88; interquartile range, 0.81 to 0.91) than in the controls (median, 0.76; interquartile range, 0.67 to 0.86; P = 0.02). Children were also less atopic (2 of 13) in the respiratory syncytial virus immune globulin group than in the control group (13 of 26, P <0.04) and were less likely to have missed school (P = 0.006) or have had an asthma attack (P = 0.03).
The results suggest that prophylaxis of respiratory syncytial virus infections in infancy may have long-term effects on respiratory and immunologic parameters relevant to the development of asthma. Larger-scale studies are needed.</description><identifier>ISSN: 0002-9343</identifier><identifier>EISSN: 1555-7162</identifier><identifier>DOI: 10.1016/S0002-9343(02)01095-1</identifier><identifier>PMID: 12034412</identifier><identifier>CODEN: AJMEAZ</identifier><language>eng</language><publisher>New York, NY: Elsevier</publisher><subject>Biological and medical sciences ; Bronchial Provocation Tests ; Case-Control Studies ; Child ; Children & youth ; Clinical outcomes ; Female ; Humans ; Immunoglobulins, Intravenous - immunology ; Immunoglobulins, Intravenous - therapeutic use ; Investigative techniques, diagnostic techniques (general aspects) ; Male ; Medical sciences ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Respiratory diseases ; Respiratory Function Tests ; Respiratory Syncytial Virus Infections - immunology ; Respiratory Syncytial Virus Infections - prevention & control ; Respiratory system ; Risk Factors</subject><ispartof>The American journal of medicine, 2002-06, Vol.112 (8), p.627-633</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Elsevier Sequoia S.A. Jun 1, 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-1c66656722a59a3f219911c2035ffe92bccd82e9ec20c63f2a83956e5fc5b8e53</citedby><cites>FETCH-LOGICAL-c362t-1c66656722a59a3f219911c2035ffe92bccd82e9ec20c63f2a83956e5fc5b8e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13716850$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12034412$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WENZEL, Sally E</creatorcontrib><creatorcontrib>GIBBS, Robyn L</creatorcontrib><creatorcontrib>LEHR, Marsha V</creatorcontrib><creatorcontrib>SIMOES, Eric A. F</creatorcontrib><title>Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with Respiratory syncytial virus immune globulin</title><title>The American journal of medicine</title><addtitle>Am J Med</addtitle><description>Respiratory syncytial virus infections have been implicated in the development of asthma. We evaluated the long-term effects of respiratory syncytial virus immune globulin, an effective prophylactic agent for the prevention of these infections in children, on respiratory and allergic outcomes in children at high risk of chronic airway disease.
Thirteen children at high risk of respiratory disease (mean [+/-SD] age, 8.6 +/- 1.1 years) were evaluated using pulmonary function and allergy skin testing 7 to 10 years after they had received prophylaxis with respiratory syncytial virus immune globulin. For comparison, 26 high-risk control children (mean age, 8.5 +/- 0.9 years) were also evaluated. Health outcomes data were collected from all subjects. The children were matched for age and gestational age. There were more boys, and a lesser frequency of a lower respiratory tract infection with respiratory syncytial virus (P <0.001) in the group that had been treated prophylactically than in the controls. The ratio of the forced expiratory volume in 1 second to forced vital capacity was significantly better in children who had received immune globulin (median, 0.88; interquartile range, 0.81 to 0.91) than in the controls (median, 0.76; interquartile range, 0.67 to 0.86; P = 0.02). Children were also less atopic (2 of 13) in the respiratory syncytial virus immune globulin group than in the control group (13 of 26, P <0.04) and were less likely to have missed school (P = 0.006) or have had an asthma attack (P = 0.03).
The results suggest that prophylaxis of respiratory syncytial virus infections in infancy may have long-term effects on respiratory and immunologic parameters relevant to the development of asthma. Larger-scale studies are needed.</description><subject>Biological and medical sciences</subject><subject>Bronchial Provocation Tests</subject><subject>Case-Control Studies</subject><subject>Child</subject><subject>Children & youth</subject><subject>Clinical outcomes</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulins, Intravenous - immunology</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Respiratory diseases</subject><subject>Respiratory Function Tests</subject><subject>Respiratory Syncytial Virus Infections - immunology</subject><subject>Respiratory Syncytial Virus Infections - prevention & control</subject><subject>Respiratory system</subject><subject>Risk Factors</subject><issn>0002-9343</issn><issn>1555-7162</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkV9LHDEUxUOx1HX1I7QEoVIfRnOTTWbnURZtBaHgn-eQzd5xYjOTbTLTOvTLm9VFpU-X5P7u4d5zCPkM7AQYqNMbxhgvKjET3xg_ZsAqWcAHMgEpZVGC4jtk8orskr2UHvIzU-oT2QXOxGwGfEL-XWNau2j6EEcaht6GFhN1HW3cfVNEl35R2zi_itjRkvaBAqMjmpioqXuMdB3Duhm9eXSJ_nV9Q9_rpbGzY--Mp39cHLJs2w4d0nsfloN33T75WBuf8GBbp-Tu4vx28aO4-vn9cnF2VViheF-AVUpJVXJuZGVEzaGqAGw-QdY1Vnxp7WrOscL8ZVXum7nIZ6KsrVzOUYopOXrRzcv-HjD1unXJovemwzAkXUIpSp5tmpLD_8CHMMQu76a54CJbNttA8gWyMaQUsdbr6FoTRw1Mb6LRz9Hoje861-doNOS5L1vxYdni6m1qm0UGvm4Bk6zxdTSddemNEznVuWTiCR0ql8E</recordid><startdate>20020601</startdate><enddate>20020601</enddate><creator>WENZEL, Sally E</creator><creator>GIBBS, Robyn L</creator><creator>LEHR, Marsha V</creator><creator>SIMOES, Eric A. F</creator><general>Elsevier</general><general>Elsevier Sequoia S.A</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20020601</creationdate><title>Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with Respiratory syncytial virus immune globulin</title><author>WENZEL, Sally E ; GIBBS, Robyn L ; LEHR, Marsha V ; SIMOES, Eric A. F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-1c66656722a59a3f219911c2035ffe92bccd82e9ec20c63f2a83956e5fc5b8e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Biological and medical sciences</topic><topic>Bronchial Provocation Tests</topic><topic>Case-Control Studies</topic><topic>Child</topic><topic>Children & youth</topic><topic>Clinical outcomes</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulins, Intravenous - immunology</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Respiratory diseases</topic><topic>Respiratory Function Tests</topic><topic>Respiratory Syncytial Virus Infections - immunology</topic><topic>Respiratory Syncytial Virus Infections - prevention & control</topic><topic>Respiratory system</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WENZEL, Sally E</creatorcontrib><creatorcontrib>GIBBS, Robyn L</creatorcontrib><creatorcontrib>LEHR, Marsha V</creatorcontrib><creatorcontrib>SIMOES, Eric A. F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WENZEL, Sally E</au><au>GIBBS, Robyn L</au><au>LEHR, Marsha V</au><au>SIMOES, Eric A. F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with Respiratory syncytial virus immune globulin</atitle><jtitle>The American journal of medicine</jtitle><addtitle>Am J Med</addtitle><date>2002-06-01</date><risdate>2002</risdate><volume>112</volume><issue>8</issue><spage>627</spage><epage>633</epage><pages>627-633</pages><issn>0002-9343</issn><eissn>1555-7162</eissn><coden>AJMEAZ</coden><abstract>Respiratory syncytial virus infections have been implicated in the development of asthma. We evaluated the long-term effects of respiratory syncytial virus immune globulin, an effective prophylactic agent for the prevention of these infections in children, on respiratory and allergic outcomes in children at high risk of chronic airway disease.
Thirteen children at high risk of respiratory disease (mean [+/-SD] age, 8.6 +/- 1.1 years) were evaluated using pulmonary function and allergy skin testing 7 to 10 years after they had received prophylaxis with respiratory syncytial virus immune globulin. For comparison, 26 high-risk control children (mean age, 8.5 +/- 0.9 years) were also evaluated. Health outcomes data were collected from all subjects. The children were matched for age and gestational age. There were more boys, and a lesser frequency of a lower respiratory tract infection with respiratory syncytial virus (P <0.001) in the group that had been treated prophylactically than in the controls. The ratio of the forced expiratory volume in 1 second to forced vital capacity was significantly better in children who had received immune globulin (median, 0.88; interquartile range, 0.81 to 0.91) than in the controls (median, 0.76; interquartile range, 0.67 to 0.86; P = 0.02). Children were also less atopic (2 of 13) in the respiratory syncytial virus immune globulin group than in the control group (13 of 26, P <0.04) and were less likely to have missed school (P = 0.006) or have had an asthma attack (P = 0.03).
The results suggest that prophylaxis of respiratory syncytial virus infections in infancy may have long-term effects on respiratory and immunologic parameters relevant to the development of asthma. Larger-scale studies are needed.</abstract><cop>New York, NY</cop><pub>Elsevier</pub><pmid>12034412</pmid><doi>10.1016/S0002-9343(02)01095-1</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9343 |
| ispartof | The American journal of medicine, 2002-06, Vol.112 (8), p.627-633 |
| issn | 0002-9343 1555-7162 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71737234 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Biological and medical sciences Bronchial Provocation Tests Case-Control Studies Child Children & youth Clinical outcomes Female Humans Immunoglobulins, Intravenous - immunology Immunoglobulins, Intravenous - therapeutic use Investigative techniques, diagnostic techniques (general aspects) Male Medical sciences Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Respiratory diseases Respiratory Function Tests Respiratory Syncytial Virus Infections - immunology Respiratory Syncytial Virus Infections - prevention & control Respiratory system Risk Factors |
| title | Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with Respiratory syncytial virus immune globulin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T23%3A07%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Respiratory%20outcomes%20in%20high-risk%20children%207%20to%2010%20years%20after%20prophylaxis%20with%20Respiratory%20syncytial%20virus%20immune%20globulin&rft.jtitle=The%20American%20journal%20of%20medicine&rft.au=WENZEL,%20Sally%20E&rft.date=2002-06-01&rft.volume=112&rft.issue=8&rft.spage=627&rft.epage=633&rft.pages=627-633&rft.issn=0002-9343&rft.eissn=1555-7162&rft.coden=AJMEAZ&rft_id=info:doi/10.1016/S0002-9343(02)01095-1&rft_dat=%3Cproquest_cross%3E71737234%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=232334444&rft_id=info:pmid/12034412&rfr_iscdi=true |